Effects of bay 10-6734 (Embusartan), a new angiotensin II type I receptor antagonist, on vascular smooth muscle cell growth

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 1, 1999, Pages 181-187

  Iouzalen, L ^a   Stepien, O ^a   Marche, P ^a  

^a Laboratoire de Pharmacologie CNRS URA 1482   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BAY 106735; DRUG METABOLITE; EMBUSARTAN; IODINE 125; LOSARTAN; UNCLASSIFIED DRUG;

ANIMAL CELL; AORTA; ARTICLE; BLOOD PRESSURE REGULATION; CALCIUM TRANSPORT; CELL CULTURE; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; CALCIUM; CELL DIVISION; CELLS, CULTURED; CYTOSOL; DIHYDROPYRIDINES; DNA; IMIDAZOLES; LOSARTAN; MALE; MUSCLE, SMOOTH, VASCULAR; PROTEIN BIOSYNTHESIS; RADIOLIGAND ASSAY; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; SPECIES SPECIFICITY; TETRAZOLES;

EID: 0032919497     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Berk BC, Vekshtein V, Gordon HM and Tsuda T (1989) Angiotensin-II stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 13: 305-314.
2. Bobik A and Campbell JH (1993) Vascular derived growth factor: Cell biology, pathophysiology and pharmacology. Pharmacol Rev 45:1-42.
3. Bohm M, Zolk O, Flesch M, Schiffer F, Schnabel P, Stasch JP and Knorr A (1998) Effects of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition on cardiac beta-adrenergic signal transduction. Hypertension 31:747-754.
4. Briand V, Riva L and Galzin AM (1994) Characterization of the angiotensin II AT1 receptor subtype involved in DNA synthesis in cultured vascular smooth muscle cells. Br J Pharmacol 112:1195-1201.
5. Bunkenburg B, van Amelsvoort T, Rogg H and Wood J (1992) Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 20:746-754.
6. Cahill PA, Redmond EM, Foster C and Sitzmann JV (1995) Nitric oxide regulates angiotensin II receptors in vascular smooth muscle cells. Eur J Pharmacol 288: 219-229.
7. Campbell-Boswell M and Robertson A (1981) Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. Exp Mol Pathol 35:265-276.
8. Catalioto RM, Porchia R, Renzetti AR, Criscuoli M, Subissi A and Giachetti A (1995) Angiotensin II-induced responses in vascular smooth muscle cells: Inhibition by non-peptide receptor antagonists. Eur J Pharmacol 280:285-292.
9. Chiu AT, Roscoe WA, McCall DE and Timmermans PBMWM (1991) Angiotensin II-1 receptors mediate both vasoconstrictor and hypertrophic responses in rat aortic smooth muscle cells. Receptor 1:133-140.
10. de Gasparo M, Whitebread S, Mele M, Motani AS, Whitcombe PJ, Ramjoue HP and Kamber B (1990) Biochemical characterization of two angiotensin II receptor subtypes in the rat. J Cardiovasc Pharmacol 16(Suppl 4):S31-S35.
11. Duff JL, Marrero MB, Paxton WG, Schieffer B, Bernstein KE and Berk BC (1995) Angiotensin II signal transduction and the mitogen-activated protein kinase pathway. Cardiovasc Res 30:511-517.
12. Dunn FW, Roux MH, Farhadian F, Sabri K, Ossart C, Samuel JL, Rappaport L and Hamon G (1997) HR 720, a novel angiotensin receptor antagonist inhibits the angiotensin II-induced trophic effects, fibronectin release and fibronectin-EIIIA(+) expression in rat aortic vascular smooth muscle cells in vitro. J Pharmacol Exp Ther 280:447-453.
13. Flesch M, Ko Y, Seul C, Düsing R, Feltkamp H, Vetter H and Sachinidis A (1995) Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells. Eur J Pharmacol 289:399-402.
14. Geisterfer AAT, Peach MJ and Owens GK (1988) Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 62:749-756.
15. Griffin SA, Brown WCB, MacPherson F, McGrath JC, Wilson VG, Koragaard N, Mulvany MJ and Lever AF (1991) Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 17:626-635.
16. 2+ indicators with greatly improved fluorescent properties. J Biol Chem 260:3440-3450.
17. Hamada M, Nishio I, Baba A, Fukuda K, Takeda J, Ura M, Hano T, Kuchii M and Masuyama Y (1990) Enhanced DNA synthesis of cultured vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 81:191-198.
18. Itazaki K, Hara M, Itoh N and Fujimoto M (1995) A long term receptor stimulation is requisite for angiotensin II-dependent DNA synthesis in vascular smooth muscle cells from spontaneously hypertensive rats. Eur J Pharmacol 291:417-425.
19. Ko Y, Görg A, Appenheimer M, Wieczorek AJ, Düsing R, Vetter H and Sachinidis A (1992) Losartan inhibits the angiotensin II-induced stimulation of the phosphoinositide signalling system in vascular smooth muscle cells. Eur J Pharmacol 227:215-219.
20. Koh E, Morimoto S, Tomita J, Rakugi H, Jiang B, Inoue T, Nabata T, Kukuo K and Ogihara T (1994) Effects of an angiotensin II receptor antagonist, CV-11974, on angiotensin II-induced increases in cytosolic free calcium concentration, hyperplasia, and hypertrophy of cultured vascular smooth muscle cells. J Cardiovasc Pharmacol 23:175-179.
21. Leduc I, Haddad P, Giasson E and Meloche S (1995) Involvement of a tyrosine kinase pathway in the growth-promoting effects of angiotensin II on aortic smooth muscle cells. Mol Pharmacol 48:582-592.
22. Lyall F, Dornan ES, McQueen J, Boswell F and Kelly M (1992) Angiotensin II increases proto-oncogene expression and phosphoinositide turnover in vascular smooth muscle cells via the angiotensin II AT1 receptor. J Hypertens 70:1463-1469.
23. Marche P, Hérembert T and Zhu DL (1995) Molecular mechanisms of vascular hypertrophy in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol (Suppl 1):S114-S116.
24. Morishita R, Gibbons GH, Ellison KE, Lee W, Zhang L, Yu H, Kameda Y, Ogihara T and Dzau VJ (1994) Evidence for direct local effect of angiotensin II in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Clin Invest 84:978-984.
25. Morton C, Baines R, Masood I, Ng L and Boarder MR (1995) Stimulation of two vascular smooth muscle-derived cell lines by angiotensin II: Differential second messenger responses leading to mitogenesis. Br J Pharmacol 115:361-367.
26. Neusser M, Tepel M and Zidek W (1993) Angiotensin II responses after protein kinase C activation in vascular smooth muscle cells of spontaneously hypertensive rats. J Cardiovasc Pharmacol 21:749-753.
27. Paquet JL, Baudouin-Legros M, Brunelle G and Meyer P (1990) Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 8:565-572.
28. Powell JS, Clozel JP, Muller RKM, Kuhn H, Hefti F, Hosang M and Baumgartner HR (1989) Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science (Wash DC) 245:186-188.
29. Ross R (1971) The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol 50:172-186.
30. Ross R (1993) The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature (London) 362:801-809.
31. Sachinidis A, Ko Y, Weisser P, Meyer zu Brickwedde MK, Düsing R, Christian R, Wieczorek AJ and Vetter H (1993) EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells. J Hypertens 11:155-162.
32. Schmitz U and Berk BC (1997) Angiotensin II signal transduction - Stimulation of multiple mitogen-activated protein kinase pathways. Trends Endocrinol Metab 8:261-266.
33. Stasch JP, Knorr A, HirthDietrich C, Kramer T, Hubsch W, Dressel J, Fey P, Beuck M, Sander E, Frobel K and Kazda S (1997) Long-term blockade of the angiotensin II receptor in renin transgenic rats, salt-loaded Dahl rats, and stroke-prone spontaneously hypertensive rats. Arzneim-Forsch/Drug Res 47:1016-1023.
34. Stepien O, Gogusev J, Zhu DL, Iouzalen L, Herembert T, Drueke TB and Marche P (1998) Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation. J Cardiovasc Pharmacol 31: 786-793.
35. Sung CP, Arleth AJ, Storer BL and Ohlstein EH (1994) Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther 271:429-437.
36. Takahashi T, Kawahara Y, Okuda M and Yokoyama M (1996) Increasing cAMP antagonizes hypertrophic response to angiotensin II without affecting ras and MAP kinase activation in vascular smooth muscle cells. FEBS Lett 397:89-92.
37. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM and Smith RD (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45:205-251.
38. Vallotton MB (1987) The renin-angiotensin system. Trends Pharmacol Sci 8:69-74.
39. Virone-Oddos A, Desangle V, Provost D, Cazes M, Caussade F and Cloarec A (1997) In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation. Br J Pharmacol 120:488-494.
40. Zhu DL, Hérembert T and Marche P (1991) Increased proliferation of adventitial fibroblasts from spontaneously hypertensive rat aorta. J Hypertens 9:1161-1168.